Steminent Biotherapeutics (ROCO:7729) ROCE %: -36.68% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7729 Steminent Biotherapeutics Inc ROCO:7729
11 GF Score
Price NT$73.00
! 4 Warning Signs
View Full Analysis

What is Steminent Biotherapeutics ROCE %?

Steminent Biotherapeutics ROCO:7729 -4.70% 11 ROCE % is -36.68% as of Dec. 2025. GuruFocus rates ROCO:7729 with a GF Score™ of 11/100. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Steminent Biotherapeutics's annualized ROCE % for the quarter that ended in Dec. 2025 was -36.68%.

Steminent Biotherapeutics  (ROCO:7729) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Steminent Biotherapeutics ROCE % Related Terms

Steminent Biotherapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Steminent Biotherapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Steminent Biotherapeutics ROCE % Chart

Steminent Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -72.56 -36.10 -33.24 -32.64 -32.29

Steminent Biotherapeutics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only -34.34 -31.97 -33.55 -42.26 -36.68
ROCO:7729
11GF Score
Steminent Biotherapeutics Inc ROCO:7729
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Steminent Biotherapeutics ROCE % Calculation

Steminent Biotherapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-171.993/( ( (436.661 - 31.727) + (698.494 - 38.145) )/ 2 )
=-171.993/( (404.934+660.349)/ 2 )
=-171.993/532.6415
=-32.29 %

Steminent Biotherapeutics's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-184.904/( ( (377.348 - 29.376) + (698.494 - 38.145) )/ 2 )
=-184.904/( ( 347.972 + 660.349 )/ 2 )
=-184.904/504.1605
=-36.68 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -36.68% mean?
Steminent Biotherapeutics (ROCO:7729) has a ROCE % of -36.68% as of Dec. 2025.
Is Steminent Biotherapeutics' ROCE % too high?
Steminent Biotherapeutics' current ROCE % is -36.68%. Overall, Steminent Biotherapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Steminent Biotherapeutics' ROCE % compare to VRTX and REGN?
Steminent Biotherapeutics' ROCE % of -36.68% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Steminent Biotherapeutics's current ROCE % is -36.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Steminent Biotherapeutics stock overvalued right now?
Steminent Biotherapeutics (ROCO:7729) has a current ROCE % of -36.68%. The current ROCE % is -36.68%. Steminent Biotherapeutics' overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Steminent Biotherapeutics (ROCO:7729), the current ROCE % is -36.68% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Steminent Biotherapeutics Business Description

Address No.16,Wenhu Street, Neihu District, Taipei, TWN, 11445
Steminent Biotherapeutics Inc is a international stem cell biopharmaceutical company which has stable and efficient stem cell platform technology, aiming to develop live cell drugs to treat degenerative diseases as well as acute and life-threatening diseases. With its Stemchymal which is proprietary technology platform generating the standardized, clinical grade, allogeneic stem cells isolated from human adipose tissue. It is operated in strict compliance to regulations of Taiwan, the US, and Japan.
11GF Score

Get the complete analysis for ROCO:7729

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$73.00
Price